Study S001248

The Effect of Lixisenatide on the Effect of Pituitary Hormones

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05804513
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: SINGLE
Status: UNKNOWN
Enrollment: 10
Start: 2023-04-17
Primary completion: 2023-10-31
Lead sponsor: University of Tartu
Conditions: Healthy; Type 1 Diabetes
Interventions: DRUG:Placebo; DRUG:Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector
Results posted: FALSE

Registered primary outcomes

Growth hormone area under the curve. [0-150 minutes after study drug administration]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.